EUCTR2019-000942-36-BE进行中（未招募）1 期
A randomized, double-blind, placebo-controlled, cross-over, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin and tapentadol on biomarkers of pain processing observed by Peripheral Nerve Excitability Testing (NET) - The effect of analgesics on biomarkers observed by nerve excitability testing
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Provision of signed and dated informed consent form
- •Stated willingness to comply with all study procedures and regimens and availability for the duration of the study
- •Caucasian male or female subjects, aged 18 years to 45 years
- •Subjects must be in good health as determined by the medical history, physical and laboratory examinations and must not show any clinically significant deviations from reference ranges as determined by 12-lead electrocardiogram (ECG), vital signs (blood pressure, pulse rate and respiratory rate) and laboratory parameters (renal and hepatic function)
- •Body mass index >18 kg/m2 and < 30 kg/m2 with a minimum body weight of 45.0 kg and a maximum of 100kg (for men and women)
- •Ability to take oral medication
- •For female subjects of childbearing potential: use of highly effective contraception with a low failure rate defined as <1% per year for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of study drug administration: -combined (estrogen and progestogen containing) hormonal contraception, -progestogen-only hormonal contraception associated with inhibition of ovulation, -an intra-uterine device (hormone-free), -an intra-uterine hormone releasing system (IUS). A woman of non-childbearing potential may be included if surgically sterile (i.e., after hysterectomy or bilateral oophorectomy) or post-menopausal for at least 2 years.
- •Right hand dominance (assessed using the Edinburgh Handedness Inventory, and defined as a score =60)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Presence of any medical devices (e.g., cardiac pacemaker), implants or protheses unless it is beyond discussion that these will not put the subject’s safety during the study at risk and will not interfere with the results of the study
- •Known or suspected allergic reactions / hypersensitivity to components of lacosamide/Vimpat®.
- •Second- or third-degree atrioventricular (AV) block.
- •Known or suspected allergic reactions / hypersensitivity to components of pregabalin/Lyrica®.
- •Known or suspected allergic reactions / hypersensitivity to components of tapentadol / Palexia®.
- •Known contraindication for drugs with µ-opioid agonist activity, i.e., significant respiratory depression, acute or severe bronchial asthma or hypercapnia.
- •Present or suspected paralytic ileus.
- •Acute intoxication with alcohol, hypnotics, centrally acting analgesics, or psychotropic drugs.
- •Not willing or able to abstain from changes in physical exercise activities during the Study.
- •Any chronic pain condition or recent (i.e. within the preceding 2 years) history thereof.
- •Migraine (at least 1 attack in the last 24 months).
- •Recurrent headache or back pain on more than 5 days/month in the last 3 months.
- •Caffeine consumption of more than 8 servings of coffee, tea, or other caffeinated drinks per day. Each serving is approximately 120mg of caffeine.
- •Any relevant symptom of neurological dysfunction of the motor and sensory system that may interfere with the conduct of the study.
- •Clinically-evident psychiatric diseases (e.g. depression, anxiety).
- •History or symptoms of central nervous system disease or peripheral nerve lesions or dysfunction with sequelae that may impact the study assessments or that may deteriorate by one dose of a drug with anti-epileptic, noradrenergic or opioid activity.
- •Focused neurological examination showing signs of abnormality.
- •Active internal disease or sequelae of internal disease (e.g. diabetes mellitus, liver diseases, kidney diseases, cardiovascular diseases, hypo- or hyperthyroidism, hypertension etc.).
- •Diseases or conditions known to interfere with the distribution, metabolism, or excretion of drugs.
- •Clinically significant disease (e.g. medical history of infection with human immunodeficiency virus (HIV) Type 1 or Type 2, hepatitis B, or hepatitis C) or condition that may affect efficacy or safety assessments, or any other reasons which, in investigator´s opinion, may preclude the subject´s participation in the trial.
- •Not willing or able to abstain from alcohol from 48 hours prior to any study period and until the end of the study period.
- •Consumption of cannabis in the last 4 weeks prior to the study.
- •Evidence or history of alcohol or drug (opioids, amphetamines, benzodiazepines, cannabinoids) abuse (as defined by ICD-10 or DSM IV) including positive or missing drugs of abuse screen (urine drugs of abuse test). Consumption of more than 21 alcohol units per week for male subjects and more than 14 units per week for female subjects (1 alcohol unit = 1 beer [12 oz/355 mL] = 1 wine [5 oz/150 mL] = 1 liquor [1.5 oz/40 mL] = 0.75 oz/20 mL alcohol).
- •Habitually smoking more than 10 cigarettes, 2 cigars, or 2 pipes of tobacco per day within the last 6 months before enrollment in this trial.
- •Known or suspected of not being willing or able to comply with the requirements of the trial protocol or the instructions.
- •Inability to communicate meaningfully with the trial site staff (e.g. insufficient language skills).
- •Any person with di
研究者
相似试验
已完成
不适用
A randomized, double-blind, placebo-controlled, crossover study on the suppressive effect of the peptide on postprandial blood glucose levelot applicableJPRN-UMIN000048002CPCC Company Limited30
已完成
1 期
A study to evaluate the prebiotic effect of Manuka Honey with Cyclopower (Trademark) capsules in healthy subjects.Gastrointestinal effect and wellnessAlternative and Complementary Medicine - Other alternative and complementary medicineOral and Gastrointestinal - Normal oral and gastrointestinal development and functionACTRN12615000857505The New Zealand Institute for Plant and Food Research20
进行中（未招募）
不适用
A study assessing the safety, tolerability and efficacy of a new medication (SER100) in patients with Isolated Systolic Hypertension (ISH) insufficiently treated with 1-3 other anti-hypertensives.MedDRA version: 14.1Level: LLTClassification code 10050591Term: Isolated systolic hypertensionSystem Organ Class: 100000004866Isolated Systolic HypertensionEUCTR2013-001227-40-HUSerodus ASA30
已完成
Unknown
A clinical trial assessing the efficacy and safety of DA-5521 in treating hangoversKCT0008927Dong-A Pharm24
已完成
2 期
A randomized, double-blind, placebo-controlled, cross-over study to assess the effects of fampridine on eye movements and nerve conduction and function in patients with multiple sclerosis (MS) and a unilateral or bilateral internuclear ophthalmoplegia (INO)nerve disease10012303multiple sclerosisNL-OMON42310Centre for Human Drug Research24